About Rezolute, Inc.
https://www.rezolutebio.comRezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
CEO
Nevan Charles Elam
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-10-13 | Reverse | 1:50 |
| 2014-05-28 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 3 of 79
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
BTIG
Buy
Maxim Group
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FEDERATED HERMES, INC.
Shares:14.03M
Value:$38.17M
FMR LLC
Shares:12.76M
Value:$34.72M
BLACKROCK, INC.
Shares:5M
Value:$13.61M
Summary
Showing Top 3 of 122
About Rezolute, Inc.
https://www.rezolutebio.comRezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $19.82M ▼ | $-18.15M ▲ | 0% | $-0.18 ▲ | $-18.14M ▲ |
| Q4-2025 | $0 | $25.85M ▲ | $-24.39M ▼ | 0% | $-0.26 ▲ | $-25.84M ▼ |
| Q3-2025 | $0 | $20.02M ▲ | $-18.91M ▼ | 0% | $-0.27 ▼ | $-20.02M ▼ |
| Q2-2025 | $0 | $17.08M ▲ | $-15.73M ▼ | 0% | $-0.22 | $-17.07M ▼ |
| Q1-2025 | $0 | $16.94M | $-15.38M | 0% | $-0.22 | $-16.93M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $152.19M ▼ | $158.66M ▼ | $11.5M ▼ | $147.17M ▼ |
| Q4-2025 | $167.86M ▲ | $175.49M ▲ | $13.36M ▲ | $162.13M ▲ |
| Q3-2025 | $86.89M ▼ | $94.74M ▼ | $12.17M ▼ | $82.57M ▼ |
| Q2-2025 | $96.54M ▼ | $112.01M ▼ | $12.42M ▲ | $99.59M ▼ |
| Q1-2025 | $108.27M | $123.41M | $9.97M | $113.44M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-18.15M ▲ | $-17.43M ▲ | $-68.49M ▼ | $911K ▼ | $-85.01M ▼ | $-17.43M ▲ |
| Q4-2025 | $-24.39M ▼ | $-22M ▼ | $346K ▼ | $101.16M ▲ | $79.51M ▲ | $-22M ▼ |
| Q3-2025 | $-18.91M ▼ | $-17.4M ▼ | $23.05M ▲ | $10K ▼ | $5.66M ▲ | $-17.4M ▼ |
| Q2-2025 | $-15.73M ▼ | $-13.67M ▲ | $11.47M ▲ | $657K ▼ | $-1.54M ▲ | $-13.67M ▲ |
| Q1-2025 | $-15.38M | $-16.01M | $-49.41M | $5.5M | $-59.92M | $-16.01M |
CEO
Nevan Charles Elam
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-10-13 | Reverse | 1:50 |
| 2014-05-28 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 3 of 79
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
BTIG
Buy
Maxim Group
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FEDERATED HERMES, INC.
Shares:14.03M
Value:$38.17M
FMR LLC
Shares:12.76M
Value:$34.72M
BLACKROCK, INC.
Shares:5M
Value:$13.61M
Summary
Showing Top 3 of 122